spin win
everi busi strong growth particular strength life
best growth yr dental rebound weak
rais core guidanc due improv underli demand share
convers continu strong
dentalco spin allow manag focu
invest high growth opportun reminisc spin
tariff expect hw take countermeasur
countermeasur take time implement
soft chemic food beverag demand chemtreat partial
off-set strong commerci primari metal
thesi updat post fantast quarter
deni furthermor dental spin long term posit
busi differ characterist parent would
drag overal organ growth thu morn
develop clear boost share look howev
magnitud today out-performance share think partli
explain spin also posit view
like exagger upsid given know macro
risk still exist tariff front share settl see
slow steadi march upward could prove catalyst rich
year spin albeit benefit non-tradit
share dental co trade discount premium parent
balanc sheet ripe deploy wherebi transact
decidedli plausibl said valuat current limit
enthusiasm modestli stock alreadi trade healthi premium
market warrant given view growth acceler capit
deploy upsid tariff nois doesnt seem subsid
may get wors get better sentiment standpoint moreso
pure fundament roll continu stick
tool group given posit medium long term fundament
acknowledg near term could choppi ep forecast
pt move higher
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
initi vs st ep vs st
 growth bp tougher comp hw
rais ep vs prior st
spin similar spin spun busi bottom cycl lead valu unlock spin-
co remain-co
tradit consumables/equip grew time sinc show earli sign market stabil
china continu strong growth driver
specialti clear align ortho grew msd
best growth life sci year
growth driven across develop
beckman grew lsd remain busi grew hsd
growth driven china develop market
strength muni industri end market drove msd qualiti w/ hach grow dd
busi hsd
develop market grew msd hsd
life strong across geographi
dx strength china na eu
hach msd growth led industri strength na china
biopharma normal soft last year bioprocess inventori adjust
 larg molecul growth driven china
appli market strength food environment test driven china larg
 fund end market good
industri end market msd pll show continu growth improv
plenti capac
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin juli et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
